Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Pilotto

Showing results (11-20 of 228) with videos related to

Pageof 23
Sort By:
Expert Review of Anticancer Therapy|February 19, 2025
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancerAlice Avancini, Ilaria Trestini, Lorenzo Belluomini, et al.
Expert Opinion on Drug Safety|April 2, 2014
Targeting the epidermal growth factor receptor in solid tumors: focus on safetyEleonora Lucchini, Sara Pilotto, Elisa Spada, et al.
Annals of Translational Medicine|February 7, 2017
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySara Pilotto, Anastasios Gkountakos, Luisa Carbognin, et al.
Expert Opinion on Biological Therapy|March 30, 2023
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancerLorenzo Belluomini, Alice Avancini, Marco Sposito, et al.
Critical Reviews in Oncology/Hematology|January 19, 2025
Real-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzlePaola Damiano, Alessio Stefani, Alice Avancini, et al.
Clinical Lung Cancer|August 10, 2024
Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is ComingAlice Avancini, Diana Giannarielli, Lorenzo Belluomini, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2022
Drive the oncologists into exercise promotion in lung cancerAlice Avancini, Lorenzo Belluomini, Michele Milella, et al.
Translational Lung Cancer Research|March 10, 2016
Cellular and molecular biology of small cell lung cancer: an overviewNiki Karachaliou, Sara Pilotto, Chiara Lazzari, et al.
Expert Review of Anticancer Therapy|April 28, 2022
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine originNicoletta Ranallo, Martine Bocchini, Jessica Menis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy numberSara Pilotto, Emilio Bria, Umberto Peretti, et al.
Pageof 23

Showing results (11-20 of 228) with videos related to

Sort By:
Pageof 23
Expert Review of Anticancer Therapy|February 19, 2025
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancerAlice Avancini, Ilaria Trestini, Lorenzo Belluomini, et al.
Expert Opinion on Drug Safety|April 2, 2014
Targeting the epidermal growth factor receptor in solid tumors: focus on safetyEleonora Lucchini, Sara Pilotto, Elisa Spada, et al.
Annals of Translational Medicine|February 7, 2017
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySara Pilotto, Anastasios Gkountakos, Luisa Carbognin, et al.
Expert Opinion on Biological Therapy|March 30, 2023
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancerLorenzo Belluomini, Alice Avancini, Marco Sposito, et al.
Critical Reviews in Oncology/Hematology|January 19, 2025
Real-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzlePaola Damiano, Alessio Stefani, Alice Avancini, et al.
Clinical Lung Cancer|August 10, 2024
Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is ComingAlice Avancini, Diana Giannarielli, Lorenzo Belluomini, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2022
Drive the oncologists into exercise promotion in lung cancerAlice Avancini, Lorenzo Belluomini, Michele Milella, et al.
Translational Lung Cancer Research|March 10, 2016
Cellular and molecular biology of small cell lung cancer: an overviewNiki Karachaliou, Sara Pilotto, Chiara Lazzari, et al.
Expert Review of Anticancer Therapy|April 28, 2022
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine originNicoletta Ranallo, Martine Bocchini, Jessica Menis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy numberSara Pilotto, Emilio Bria, Umberto Peretti, et al.
Pageof 23